<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58716">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01926834</url>
  </required_header>
  <id_info>
    <org_study_id>1201/01/006284</org_study_id>
    <nct_id>NCT01926834</nct_id>
  </id_info>
  <brief_title>The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels</brief_title>
  <official_title>The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou University of Traditional Chinese Medicine</source>
  <oversight_info>
    <authority>China: State Administration of Traditional Chinese Medicine of the People's Republic of China</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after
      acute cerebral infarction,test is made by random double-blind controlled.patients with acute
      cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin
      group,and health people. The main indexes are the serum level of  VEGF, MMP-9 and EPC.The
      review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function
      of promoting angiogenesis in multiple targets through this test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE:

      To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after
      acute cerebral infarction.

      METHOD:

      40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were
      divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people.
      Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior
      treatment,the posttreatment 1th, 3th and 7th day,and tested the level of  VEGF, MMP-9 and
      EPC.Tested the health people one time.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the serum level of VEGF,MMP-9 and EPC</measure>
    <time_frame>0-7days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health of stroke scale</measure>
    <time_frame>0-7days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Erigeron Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erigeron Injection, 30ml,qd,i.v., for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline, 500ml,i.v.,qd, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>health volunteers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>health volunteers, no drug to be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erigeron Injection</intervention_name>
    <description>Erigeron Injection, 30ml, iv, qd, for 7days</description>
    <arm_group_label>Erigeron Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>normal saline, 500ml,i.v.,qd, for 7 days</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>normal saline, 500ml,i.v.,qd, for 7 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged no younger than 18yrs

          -  attack within 72 hours

          -  NIHSS score in the 2-25 points

          -  Ischemic Stroke occurred for the first time, or with a history of stroke disease but
             without sequelae

          -  Signed the informed consents

        Exclusion Criteria:

          -  patients aged younger than 18yrs

          -  Patients with tumor, coronary heart disease, valvular heart disease, psoriasis,
             rheumatism, hematologic diseases, infertility, varieties of acute inflammation

          -  Patients with severe cognitive impairment

          -  Refused to cooperate or been unable to cooperation for neurological disorders

          -  Cerebral hemorrhage or hemorrhagic cerebral infarction

          -  Unstable vital signs dued to massive cerebral infarction

          -  Patients with serious heart, liver and renal insufficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianwen m Guo, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Province Hospital of Tradtional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianwen Guo, doctor</last_name>
    <phone>0086-13724899379</phone>
    <email>jianwen_guo@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yefeng Cai, master</last_name>
    <phone>(08620)81887233</phone>
    <phone_ext>34530</phone_ext>
    <email>caiyefeng@126.com</email>
  </overall_contact_backup>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>August 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>promoting angiogenesis in multiple targets</keyword>
  <keyword>herbal medicine</keyword>
  <keyword>traditional chinese medicine</keyword>
  <keyword>random clinical trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
